An increase of these receptors is reported in several tumors, comprising colorectal, breast, malignant head and neck neoplasms, non-small-cell lung cancer, prostate, ovarian, cervical, stomach, and pancreatic cancer [121], and in clinical activity, substances that modify the function of EGFR are progressively more utilized. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.